Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Timed-Release Glaucoma Drug Insert as Alternative to Daily Drops

May 5, 2016 9:40 am | by American Academy of Ophthalmology | News | Comments

A new device that slowly releases eye medication may one day be a promising option for the many glaucoma patients who struggle with administering their own daily prescription eye drops.

TOPICS:

'Kidney on a Chip' Could Lead to Safer Drug Dosing

May 5, 2016 9:13 am | by University of Michigan | News | Comments

The new technique could lead to more precise dosing of drugs, including some potentially toxic medicines often delivered in intensive care units.

TOPICS:

Starving Cancer The Key to New Treatments

May 5, 2016 9:08 am | by Australian National Laboratory | News | Comments

Researchers have identified a vital supply route that cancer cells use to obtain their nutrients.

TOPICS:
Advertisement

Merck Beats 1Q Profit Views with Tight Cost Controls

May 5, 2016 9:04 am | by Linda A. Johnson, AP Business Writer | News | Comments

The second-biggest U.S. drugmaker on Thursday nudged up its 2016 financial forecasts and its shares edged up in premarket trading.

TOPICS:

Effective New Drugs to Raise Heart Failure Market Value to $11.8B

May 5, 2016 8:37 am | by Elizabeth Hamson, Ph.D., Cardiovascular and Metabolic Disorders Analyst, GlobalData | Articles | Comments

Entresto has struggled to penetrate the chronic heart failure market, achieving dismal sales in the US since its launch in July 2015.

TOPICS:

Takeda's Brintellix Renamed Trintellix

May 5, 2016 8:35 am | News | Comments

The formulation, indication and dosages of Trintellix remain the same as that of Brintellix.

TOPICS:

FDA Warns Abilify Linked to Compulsive Urges

May 5, 2016 8:34 am | by Ryan Bushey, Digital Editor | Articles | Comments

The Food and Drug Administration issued a warning on Tuesday that reports of compulsive binge-eating, shopping, gambling, and sex have been connected to the antipsychotic Abilify.

TOPICS:

Ketamine Lifts Depression Via Byproduct of its Metabolism

May 5, 2016 8:10 am | by National Institute of Health | News | Comments

Clinical trials by Zarate and others have shown that ketamine can lift depression in hours, or even minutes.

TOPICS:
Advertisement

AstraZeneca Completes Acquisition of Takeda's Respiratory Business

May 5, 2016 8:00 am | News | Comments

AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.

TOPICS:

CVS Health Tops Street 1Q Forecasts

May 5, 2016 7:30 am | by The Associated Press | News | Comments

Specialty drugs and retail expansions boosted CVS Health's first-quarter revenue by 18.9 percent, helping to offset higher costs and push results above Wall Street expectations.

TOPICS:

Regeneron Pain Drug Clears Late-Stage Trial

May 4, 2016 4:00 pm | by Amrutha Penumudi, Reuters | News | Comments

The drug was tested on 421 patients with a history of inadequate pain relief or intolerance to current pain killers.

TOPICS:

Bayer's Prostate Cancer Drug Improves Survival Rates in Phase 3 Study

May 4, 2016 3:38 pm | News | Comments

Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

TOPICS:

Searching for Signs of Disease in Spit

May 4, 2016 2:00 pm | by American Chemical Society | News | Comments

Testing for health conditions usually involves needles, X-rays and other invasive or uncomfortable measures.

TOPICS:

Nano-Capsules Promise Targeted Drug Delivery

May 4, 2016 1:00 pm | by Lomonosov Moscow State University | News | Comments

Synthesis of the nanogel capsules and the related measurements were conducted in Europe.

TOPICS:

Biogen to Spin Off Hemophilia Unit, Focus on Neurodegenerative Drugs

May 4, 2016 12:25 pm | by Stephanie Guzowski, Editor | News | Comments

Biogen announced the company plans to spin off its hemophilia drug business as a publicly traded company, and instead concentrate on developing treatments for neurodegenerative diseases, primarily multiple sclerosis (MS). The move is surprising analysts.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading